Biocon Limited

Biocon Limited is an esteemed biopharmaceutical company headquartered in Bengaluru, India. Established in 1978 by Dr. Kiran Mazumdar-Shaw, who presently serves as the executive chairperson of the organization. Biocon boasts of being one of the largest and most diversified biopharmaceutical companies in Asia and operates in over 120 countries worldwide. The company has four main business segments, namely generics, biosimilars, research services, and novel biologics. As of 2022, Biocon's revenue stood at around INR 7,000 crores, a testament to its profitability and success.

Biocon's generics segment offers a wide range of active pharmaceutical ingredients (APIs) and formulations for chronic therapies such as diabetes, oncology, immunology, and nephrology. Moreover, Biocon's research services business, Syngene International, is a reputable contract research organization that provides end-to-end discovery, development, and manufacturing services to global pharma, biotech, and specialty chemical companies. Lastly, Biocon's novel biologics business is dedicated to developing innovative therapies for unmet medical needs such as oral insulin, immuno-oncology, and anti-infectives, demonstrating its commitment to advancing the healthcare industry.

Biocon is committed to social responsibility and sustainability through its CSR arm, Biocon Foundation, which works in the areas of health, education, environment, and community development. Biocon Foundation also runs Biocon Academy, a center of excellence for advanced learning in applied biosciences. Biocon has been recognized as one of the world's most innovative companies by Forbes and as one of the best employers in India by Business Today. Biocon has over 12,000 employees across India and overseas offices in the USA, Europe, the Middle East, and Asia-Pacific.

Foundation: 1978
Headquarters: Bengaluru, Karnataka

Website: https://www.biocon.com/